Demonstrating efficacy and safety in Alzheimer’s trials is complex
– we can help
As Alzheimer’s disease trials become more complex and regulators demand clearer evidence, you need better ways to navigate essential efficacy, safety, and biomarker endpoints.
Watch the free webinar replay to learn how modern endpoint data strategies and technologies can support higher quality clinical trial data.
The challenges of complex clinical trials
Alzheimer’s disease and dementia trials are among the most complex in clinical research. Sponsors must measure subtle cognitive changes, capture functional outcomes, monitor safety risks, and integrate data across multiple modalities.
As trial complexity grows, sponsors can struggle to translate data endpoints into a consistent, reliable strategy. Without a coordinated approach, studies can face:
- Increased operational burden
- Inconsistent data quality
- Delayed decision-making
- Greater regulatory risk
Our webinar replay will discuss these challenges, and the best practices to mitigate potential issues.
A more integrated approach to endpoint strategy
Modern endpoint strategies for Alzheimer’s disease trials combine scientific expertise, effective technology, and global operational scale to reduce complexity and improve outcomes.
Clario’s solutions deliver:
Stronger efficacy measurement through validated cognitive and functional endpoints
Comprehensive safety monitoring including cardiac and imaging signals
Integrated multimodal data across eCOA, imaging, motion, and more
Regulatory-ready insights that support approval pathways
Unified across every endpoint
As Alzheimer’s and dementia trials continue to grow more complex, no single endpoint tells the full story. Clario’s integrated solutions include comprehensive endpoints to monitor both safety and efficacy.
eCOA
- Improve efficiency with a validated assessment library
- Enhance data quality with built-in scoring algorithms and real-time data monitoring
- Reduce rater variability with centralized review
Medical Imaging
- Leverage MRI and PET to determine eligibility, efficacy, and safety
- Deploy ARIA monitoring for anti-amyloid therapies
- Integrate quantitative biomarker analysis including amyloid and tau
Cardiac Safety
- Measure cardiac safety through comprehensive ECG monitoring and QT analysis
- Empower earlier decisions through early phase safety insights with advanced methodologies
Precision Motion
- Objectively measure disease impact with gait, balance, activity, and sleep tracking
- Detect subtle changes earlier that reflect real-world impact
Don't let fragmented endpoints slow your Alzheimer's trial
Watch the webinar replay to explore how integrated eCOA, Cardiac Safety, and Medical Imaging from an experienced partner can elevate accuracy, efficiency, and scalability in your studies.